Navigating the Evolving Standards of Newly Diagnosed Multiple Myeloma Treatment: Exploring the Evidence on New Combination Strategies

ACTIVITY DESCRIPTION
The goal of treatment for newly diagnosed multiple myeloma (NDMM) patients is achieving the deepest possible remission, which typically involves aiming for minimal residual disease negativity. Frontline therapy for NDMM is evolving to include novel induction regimens with anti-CD38 antibodies, which have been shown to yield improved depth of response after induction. These new frontline treatments vary in induction regimen composition and use of transplant, consolidation, and maintenance therapy. Patient- and disease-related factors (including high-risk genetics, frailty, and transplant eligibility), as well as treatment-related toxicities, complicate treatment decisions for health care providers (HCPs). In addition, supportive care interventions aimed at minimizing the risk of infection and other treatment-related adverse events (AEs) are critical for maintaining quality of life and ensuring that patients remain on therapy.

Educational Objectives
After completing this activity, participants should be better able to:
- Select new anti-CD38 antibody-based four-drug treatment combinations for NDMM patients based on the latest clinical trial efficacy and safety findings
- Design a personalized treatment plan for NDMM patients, incorporating key evidence-based strategies to achieve disease remission and proactively mitigate and manage AEs